From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 1994
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.24
Pain Relevance 0.89

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

protein transporter activity (Ap3b1) transport (Ap3b1) vesicle-mediated transport (Ap3b1)
Golgi apparatus (Ap3b1)
Anatomy Link Frequency
AP-3 1
Ap3b1 (Mus musculus)
Ap3b1 - I304N (1)
Pain Link Frequency Relevance Heat
Glutamate receptor 3 99.60 Very High Very High Very High
antagonist 3 99.14 Very High Very High Very High
tetrodotoxin 2 98.82 Very High Very High Very High
Glutamate 5 98.12 Very High Very High Very High
gABA 5 95.08 Very High Very High Very High
ischemia 6 92.12 High High
cerebral cortex 2 86.84 High High
Calcium channel 1 85.92 High High
adenocard 1 63.68 Quite High
Neurotransmitter 1 25.00 Low Low
Disease Link Frequency Relevance Heat
Disease 9 99.70 Very High Very High Very High
Fragile X Syndrome 21 97.92 Very High Very High Very High
Keloid Scars 11 92.60 High High
Cv Unclassified Under Development 5 92.12 High High
Cv General 4 Under Development 1 89.92 High High
Contusions 22 89.36 High High
Severe Combined Immunodeficiency 15 87.60 High High
Injury 113 72.56 Quite High
Cognitive Disorder 2 67.68 Quite High
Spinal Cord Injury 9 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Tetrodotoxin and antagonists of glutamate receptors (DNQX, MK-801, and AP-3) depressed the initial rate of increase in extracellular glutamate and aspartate without altering the total amount of these amino acids collected in the cortical superfusates.
Negative_regulation (depressed) of AP-3 in AP-3 associated with tetrodotoxin, glutamate, glutamate receptor and antagonist
1) Confidence 0.01 Published 1994 Journal Brain Res. Bull. Section Abstract Doc Link 7915962 Disease Relevance 0.26 Pain Relevance 0.89
However, we appreciate that human deletions and the point mutation patient, to the extent that they share all the symptoms of Fragile X Syndrome, argue against the CGG repeat expansion itself playing a significant role in the disease, and that the I304N mutation is limited in clinical significance relative to the CGG expansion.
Negative_regulation (limited) of I304N mutation (I304N) associated with disease and fragile x syndrome
2) Confidence 0.01 Published 2009 Journal PLoS Genetics Section Body Doc Link PMC2779495 Disease Relevance 0.55 Pain Relevance 0
Additionally, biochemical protein analysis supplemented our stereological quantification and demonstrated no changes in protein expression levels of Fibronectin, NG2, Versican, GFAP, and PE-CAM1 at 2 weeks post-transplant.
Negative_regulation (levels) of PE-CAM1
3) Confidence 0.01 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2690693 Disease Relevance 0.43 Pain Relevance 0

General Comments

This test has worked.

Personal tools